menu
    • menu
    [{"orgOrder":0,"company":"VarmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Preclinical","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VarmX \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VarmX \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Series B Financing","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Undisclosed","graph3":"VarmX","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"VarmX \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"VarmX \/ Ysios Capital"},{"orgOrder":0,"company":"VarmX","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2025","type":"Collaboration","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Phase I","graph3":"VarmX","amount2":2.2200000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":2.2200000000000002,"dosageForm":"Infusion","sponsorNew":"VarmX \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"VarmX \/ CSL"}]

    Find Clinical Drug Pipeline Developments & Deals by VarmX

    Menu

    VarmX

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : CSL

                            Deal Size : $2,217.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            VarmX Partners With CSL in a Strategic Collab to Coagulation Treatment

                            Details : The collaboration aims to support the development of its lead asset, VMX-C001, a novel treatment to help restore blood coagulation in patients requiring urgent surgery.

                            Product Name : VMX-C001

                            Product Type : Enzyme

                            Upfront Cash : $117.0 million

                            September 16, 2025

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : CSL

                            Deal Size : $2,217.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

                            Details : VMX-C001 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blood Coagulation Disorders.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 24, 2024

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant

                            Details : VMX-C001 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blood Coagulation Disorders.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            April 18, 2024

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

                            Details : Company announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001able to rapidly and effectively restore coagulation in the presence of FXa DOAC, the Trial will assess safety, tolerability, PK and PD.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            December 15, 2021

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants ...

                            Details : VMX-C001 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blood Coagulation Disorders.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            December 09, 2021

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            VarmX

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Ysios Capital

                            Deal Size : $36.6 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            VarmX Raises €32 Million to Develop Innovative Reversal Agent for the Treatment of Bleeding in Patients on O...

                            Details : Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            July 08, 2020

                            Lead Product(s) : VMX-C001

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Ysios Capital

                            Deal Size : $36.6 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth